Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Statement | 18 May 2026 Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement – WHA79/13.3
Statement | 18 May 2026 Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases – WHA79/12.1
Press release | 18 May 2026 Urgent action needed to close devastating vaccination coverage gaps in conflict-affected settings
Press release | 15 May 2026 Countries must lay groundwork to turn Pandemic Agreement commitments into access for all
Letter | 17 April 2026 Open letter: Linking pathogens and data access to enforceable benefit-sharing commitments in the Pandemic Agreement
Report | 09 April 2026 AfricaKenyaRwandaSouth Africa Shifting Global Health R&D Funding: Opportunities in a Changing Landscape
Press release | 30 March 2026 Gilead refuses to sell groundbreaking HIV prevention drug to MSF In an open letter published today, Doctors Without Borders/Médecins Sans Frontières (MSF) called on the US pharmaceutical corporation Gilead Sciences to immediately sell the organization the game-changing and highly effective HIV prevention medicine, lenacapavir, for use in its medical programs worldwide. Despite multiple requests, the company has refused to sell lenacapavir directly to MSF.
Video Video | 26 May 2011 HIV/AIDS Mozambique Mozambique: Empowering HIV+ people to manage their care
Video Video | 26 May 2011 HIV/AIDS Malawi Malawi: Reducing pressure on health services by task-shifting
Press release | 11 May 2011 HIV/AIDS MalawiZimbabwe MSF Report: Fragile Progress as Several Countries Upgrade to Better AIDS Treatment
Feature story | 03 May 2011 HIV/AIDS Mozambique Fighting HIV/AIDS: A long battle with an uncertain outcome 6 min
Press release | 25 April 2011 HIV/AIDS Intellectual property and trade Johnson & Johnson Turns Its Back on AIDS Patients